Current Approaches to Management of Bone Sarcomas in Adolescent and Young Adult (AYA) Patients

Bone sarcomas are routinely diagnosed in the adolescent and young adult population. Successful treatment of these tumors in this population requires an understanding of tumor biology, overall treatment paradigm, modern surgical approaches, advanced radiation technologies, and long-term management of treatment associated sequelae. This activity designed as a tumor board, reviews and discusses modern surgery approaches, advanced radiation planning techniques, and assessment and management of functional outcomes for common bone sarcomas diagnosed in the adolescent and young adult (AYA) population. 

The cancer stem cell hypothesis was first proposed more than 100 years ago, and for the last 20 years the study of cancer stem cells (CSCs) has emerged as an area of intense interest after the first identification of CSCs in solid tumors. CSCs are a subpopulation of cancer cells that possess the ability to self-renew, repopulate after sublethal therapy and differentiate into multiple cell types. They are believed to be responsible for the initiation and progression of cancer, as well as the resistance to therapy. CSCs are known to be resistant to radiation therapy due to their ability to repair DNA damage, activate survival pathways, and form a protective niche. However, researchers are investigating ways to overcome these challenges and target CSCs in order to improve the effectiveness of radiation treatment. The goal of this activity is to review current understanding of CSCs, how they interact with the tumor microenvironment, contribute to tumor resistance to therapy, recurrence and metastasis as well as review strategies to target this population in a variety of cancer types.

Topic:

  1. Tumor Board Discussion of a Case Incorporating Radiation Approaches and Strategies, Modern Surgical Approaches, and Assessment and Management of Functional Outcomes in AYA Patients Diagnosed with Bone Sarcomas / Q&A 
    Safia K. Ahmed, MD
    Bree R. Eaton, MD
    Alexandra Callan, MD
    Brian DeFeo, PT, DPT, OCS

This activity is available from June 25, 2024, through 11:59 p.m. Eastern time on June 24, 2026. 

This activity was originally recorded at the 2023 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of radiation oncologists and surgeons.   

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Effectively convey the pros and cons of surgery and radiation therapy to AYA patients diagnosed with bone sarcomas and other members of the multidisciplinary sarcoma team.
  • Understand assessment and management of functional outcomes in AYA patients treated for bone sarcomas.   
  • Safely use advanced radiation therapy approaches in AYA patients diagnosed with bone sarcomas. 
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
06/25/2024
Course expires: 
06/24/2026
Cost:
$0.00
Rating: 
0
  • Safia K. Ahmed, MD, is employed by the Mayo Clinic Arizona.
  • Bree R. Eaton, MD, is employed by the Winship Cancer Institute of Emory University.  
  • Alexandra Callan, MD, is employed by UT Southwestern. Dr. Callan receives compensation from Bone Support, Inc. Dr. Callan serves on the Medical Board of Directors of MTF Biologics.  
  • Brian DeFeo, PT, DPT, OCS, is employed by St. Jude's Children's Research Hospital. 

The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
 

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website until June 24, 2026, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.